Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 09, 2026 | June 11, 2026 |
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director | December 02, 2021 | December 03, 2021 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | May 05, 2020 | May 28, 2020 |
| Epiphany Technology Acquisition Corp.EPHY · Entity 123266 | Director | September 16, 2022 | October 04, 2022 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,193 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 1,505 · Balance 15,193 F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 03, 2021
This filing explicitly reported no securities owned.
CHINOOK THERAPEUTICS, INC.
Report date May 05, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-05-04 | Direct | 30,000 |
Reported balance
After 2020-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant.
Epiphany Technology Acquisition Corp.
Report date September 16, 2022 · Filed October 04, 2022
This filing explicitly reported no securities owned.
NEUROCRINE BIOSCIENCES INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,860 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Gift · Disposed 1,000 · Balance 14,860 F1: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a gift/charitable contribution effective September 2, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neon Therapeutics, Inc.
Report date May 06, 2020 · Filed May 07, 2020
Section 16 reporting ended · disclosed 2020-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 1
1 source rowRow 1 · 2020-05-06 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-06 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-06 · Disposition to issuer · Disposed 18,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 | Direct | 0 |
Reported balance
After 2020-05-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-06 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted.
F2: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2020 Filed Dec 8, 2020 00:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GiftCommon Stock | 2,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062016 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,055 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:24 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019033 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,328 Read SEC document |
| May 19, 2020 Filed May 21, 2020 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 6,018 | $0.00 Strike: $119.93 | $0.00 |
DisclosureSEC source: 0001209191-20-031502 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,018 Underlying: Common Stock · 6,018 shares Expires 2030-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2020. Read SEC document |
| May 06, 2020 Filed May 7, 2020 01:08 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001694187-20-000070 · wf-form4_158881369954858.xml · derivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option which was outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) was cancelled and converted automatically into the right to receive, as soon as reasonably practicable after the Effective Time (but no later than ten business days thereafter), a cash payment in an amount equal to the product of (i) the total number of Shares subject to such option immediately prior to such cancellation and (ii) the excess, if any, of the Cash Merger Consideration over the exercise price per Share subject to such option immediately prior to such cancellation. Read SEC document |
| May 06, 2020 Filed May 7, 2020 01:08 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001694187-20-000070 · wf-form4_158881369954858.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| May 06, 2020 Filed May 7, 2020 01:08 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001694187-20-000070 · wf-form4_158881369954858.xml · derivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration"). Read SEC document |
| May 06, 2020 Filed May 7, 2020 01:08 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | Disposition to issuerCommon Stock | 45,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001694187-20-000070 · wf-form4_158881369954858.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. Read SEC document |
| May 05, 2020 Filed May 28, 2020 23:56 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011286 · doc1.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 20:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 17,687 | $99.39 | $1,757,965.76 |
DisclosureSEC source: 0001209191-20-026306 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,861 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.34 to $102.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,355 | Not disclosed Strike: $59.82 | Not disclosed |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · derivative · entry 6 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,355 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · derivative.underlying_shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,923 | Not disclosed Strike: $59.82 | Not disclosed |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · derivative · entry 5 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,923 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The stock options become exercisable in three (3) equal annual installments commencing one year after the grant date of 03/22/2010. F2 · derivative.underlying_shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 270 | $295.29 | $79,728.30 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,438 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,355 | $58.46 | $79,213.30 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 2,164 | $295.22 | $638,845.26 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,353 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 10,923 | $58.46 | $638,558.58 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| November 04, 2019 Filed Feb 10, 2020 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,594 Read SEC document |
| November 04, 2019 Filed Feb 10, 2020 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,594 Read SEC document |
| November 04, 2019 Filed Feb 10, 2020 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 325 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004705 · form5.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,594 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 12:27 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantCommon Stock · Derivative | 18,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001694187-19-000052 · wf-form4_156163844021811.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option was granted on June 25, 2019 with respect to 18,500 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 22:00 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022431 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,319 Read SEC document |
| May 22, 2019 Filed May 23, 2019 21:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 10,000 | $0.00 Strike: $79.79 | $0.00 |
DisclosureSEC source: 0001209191-19-032388 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2019. Read SEC document |
| May 14, 2019 Filed May 15, 2019 23:04 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001567619-19-011355 · doc1.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 14, 2019, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| October 31, 2018 Filed Nov 5, 2018 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,164 Read SEC document |
| October 31, 2018 Filed Nov 5, 2018 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,339 Read SEC document |
| October 31, 2018 Filed Nov 5, 2018 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,539 Read SEC document |
| October 31, 2018 Filed Nov 5, 2018 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 275 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032080 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,739 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020935 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,014 Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 16:34 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $98.44 | $984,420.00 |
DisclosureSEC source: 0001209191-18-037379 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,548 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.46 to $99.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:24 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001140361-18-027910 · doc1.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of June 6, 2018, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| May 24, 2018 Filed May 26, 2018 00:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 12,500 | $0.00 Strike: $94.64 | $0.00 |
DisclosureSEC source: 0001209191-18-033640 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-24 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 24, 2018. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $7.05 Strike: $7.05 | $105,750.00 |
DisclosureSEC source: 0001209191-18-026832 · doc4.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,331 | $79.44 | $105,734.64 |
DisclosureSEC source: 0001209191-18-026832 · doc4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,548 F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's 2003 Incentive Stock Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the April 26, 2018 market close price ($79.44), and this net amount ($72.39) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,669 shares to the optionee. The 1,331 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $7.05 | $105,750.00 |
DisclosureSEC source: 0001209191-18-026832 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's 2003 Incentive Stock Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the April 26, 2018 market close price ($79.44), and this net amount ($72.39) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,669 shares to the optionee. The 1,331 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| November 29, 2017 Filed Dec 5, 2017 21:29 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-033932 · form4.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,134 Read SEC document |
| November 29, 2017 Filed Dec 5, 2017 21:29 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-033932 · form4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,534 Read SEC document |
| November 29, 2017 Filed Dec 5, 2017 21:29 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-033932 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:19 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-17-039224 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of June 8, 2017, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:54 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021101 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,984 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| May 22, 2017 Filed Jun 8, 2017 22:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038638 · doc4.xml · derivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · derivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,169 | $43.60 | $50,968.40 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,879 F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the February 7, 2017 market close price ($43.60), and this net amount ($40.20) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,831 shares to the optionee. The 1,169 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $3.40 | $51,000.00 |
DisclosureSEC source: 0001209191-17-008908 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the February 7, 2017 market close price ($43.60), and this net amount ($40.20) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,831 shares to the optionee. The 1,169 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| November 08, 2016 Filed Nov 14, 2016 21:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-066963 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,905 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.